
|Articles|March 26, 2015
- Immunotherapy (Issue 5)
- Volume 5
- Issue 1
The Rationale for Immunotherapy in NSCLC
Author(s)Heather Wakelee, MD
Heather Wakelee, MD, associate professor of medicine, oncology division, Stanford University, discusses the rationale for immunotherapy in non-small cell lung cancer (NSCLC).
Advertisement
Heather Wakelee, MD, associate professor of medicine, oncology division, Stanford University, discusses the rationale for immunotherapy in non-small cell lung cancer (NSCLC).
<<<
Articles in this issue
almost 11 years ago
Maximizing Immunotherapy Approaches in Hard-to-Treat Cancersalmost 11 years ago
Rich Immunotherapy Pipeline for Melanoma Under Wayalmost 11 years ago
Tumor Antigens and Their Role in Immune Response in Melanomaalmost 11 years ago
Major Programs Under Way in Immuno-Oncologyalmost 11 years ago
PD-1 Inhibitors for Melanomaalmost 11 years ago
Immunotherapy in GU Cancersalmost 11 years ago
Immune-Related AEs and Their Management: Q & A With Michael A. Postow, MDAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















